Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R, comprise 7%–23% of EGFR mutation‐positive NSCLC. The treatme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Shijubou, Naoki, Sumi, Toshiyuki, Kamada, Koki, Sawai, Takeyuki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2021
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952783/
https://ncbi.nlm.nih.gov/pubmed/33533191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados